Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins.

Molecular cancer therapeutics - 1 Mar 2011

Minematsu Tsuyoshi, Giacomini Kathleen M

Abstract excerpt

The drug-drug interaction (DDI) potential of tyrosine kinase inhibitors (TKI) as interacting drugs via transporter inhibition has not been fully assessed. Here, we estimated the half maximal inhibitory concentration (IC(50)) values for 8 small-molecule TKIs (imatinib, dasatinib, nilotinib, gefiti...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Transport
Share to Drug Interactions
Share to HEK293 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Organic Cation Transport Proteins

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Reverse Transcriptase Polymerase Chain Reaction

Source

Open in PubMed Open full text

Identifiers

PMID: 21252289
DOI: 10.1158/1535-7163.MCT-10-0731
PMCID: PMC3063525

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21252289-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins.PMID 21252289Read ↗

Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences.Semantic proximity Read ↗

Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy.Semantic proximity Read ↗

Quantitative contributions of hepatic and renal organic cation transporters to the clinical pharmacokinetic cimetidine-metformin interactionSemantic proximity Read ↗

Predicting OCT2 / MATEs ‐Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium)Semantic proximity Read ↗

Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics.Semantic proximity Read ↗

Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms.Semantic proximity Read ↗

Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.Semantic proximity Read ↗

Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.Semantic proximity Read ↗

Genetic variation in organic cation transporters and considerations in drug development.Semantic proximity Read ↗

Organic cation transporters.Semantic proximity Read ↗

Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics.Semantic proximity Read ↗

Interaction of Tyrosine Kinase Inhibitors with the MDR-Related ABC Transporter ProteinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.